Charles River Laboratories International Inc $ 156.93 2.36 (1.53%)
Volume:
297,133
Avg Vol (1m):
305,420
Market Cap $:
7.66 Bil
Enterprise Value $:
9.56 Bil
P/E (TTM):
33.69
P/B:
5.00
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.08 | ||
| Equity-to-Asset | 0.33 | ||
| Debt-to-Equity | 1.34 | ||
| Debt-to-EBITDA | 3.99 | ||
| Interest Coverage | 6.47 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 2.42 | ||
| Beneish M-Score | -2.62 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 13.62 | ||
| Net Margin % | 9.14 | ||
| ROE % | 16.63 | ||
| ROA % | 5.56 | ||
| ROC (Joel Greenblatt) % | 29.21 | ||
| 3-Year Revenue Growth Rate | 17.3 | ||
| 3-Year EBITDA Growth Rate | 17.3 | ||
| 3-Year EPS without NRI Growth Rate | 13.4 |
Valuation Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 33.69 | ||
| Forward PE Ratio | 20.83 | ||
| PE Ratio without NRI | 33.69 | ||
| Price-to-Owner-Earnings | 25.84 | ||
| PB Ratio | 5 | ||
| PS Ratio | 3.05 | ||
| Price-to-Free-Cash-Flow | 26.33 | ||
| Price-to-Operating-Cash-Flow | 17.59 | ||
| EV-to-EBIT | 29.25 | ||
| EV-to-EBITDA | 18.57 | ||
| EV-to-Revenue | 3.76 | ||
| PEG Ratio | 2.2 | ||
| Shiller PE Ratio | 72.6 | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.2 | ||
| Days Inventory | 30.56 | ||
| Days Sales Outstanding | 56.83 | ||
| Days Payable | 24.32 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.57 | ||
| Price-to-Median-PS-Value | 1.33 | ||
| Price-to-Peter-Lynch-Fair-Value | 2.24 | ||
| Earnings Yield (Greenblatt) % | 3.43 | ||
| Forward Rate of Return (Yacktman) % | 18.58 |